Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Common Equity (2016 - 2025)

Historic Common Equity for AC Immune (ACIU) over the last 12 years, with Q3 2025 value amounting to $78.1 million.

  • AC Immune's Common Equity fell 4804.25% to $78.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.1 million, marking a year-over-year decrease of 4804.25%. This contributed to the annual value of $128.2 million for FY2024, which is 9992.92% down from last year.
  • As of Q3 2025, AC Immune's Common Equity stood at $78.1 million, which was down 4804.25% from $90.3 million recorded in Q2 2025.
  • Over the past 5 years, AC Immune's Common Equity peaked at $229.4 billion during Q1 2021, and registered a low of $78.1 million during Q3 2025.
  • Over the past 5 years, AC Immune's median Common Equity value was $165.8 million (recorded in 2024), while the average stood at $42.9 billion.
  • In the last 5 years, AC Immune's Common Equity skyrocketed by 10314101.95% in 2023 and then plummeted by 9992.92% in 2024.
  • AC Immune's Common Equity (Quarter) stood at $251.6 million in 2021, then tumbled by 30.27% to $175.4 million in 2022, then soared by 103141.02% to $181.1 billion in 2023, then crashed by 99.93% to $128.2 million in 2024, then tumbled by 39.09% to $78.1 million in 2025.
  • Its last three reported values are $78.1 million in Q3 2025, $90.3 million for Q2 2025, and $105.4 million during Q1 2025.